Development of a facile antibody-drug conjugate platform for increased stability and homogeneity

被引:30
作者
Gupta, Nimish [1 ,2 ,4 ]
Kancharla, Johny [1 ]
Kaushik, Shelly [1 ]
Ansari, Aasif [1 ]
Hossain, Samad [1 ,2 ,4 ]
Goyal, Ravinder [1 ]
Pandey, Manoj [1 ]
Sivaccumar, Jwala [1 ]
Hussain, Sazid [1 ]
Sarkar, Arindam [1 ,2 ,4 ]
Sengupta, Aniruddha [1 ,2 ,4 ]
Mandal, Swadhin K. [3 ]
Roy, Monideepa [1 ,2 ,4 ]
Sengupta, Shiladitya [1 ,2 ,5 ,6 ]
机构
[1] Invictus Oncol Pvt Ltd, Delhi 110092, India
[2] India Innovat Res Ctr, Delhi 110092, India
[3] Indian Inst Sci Educ & Res Kolkata, Dept Chem Sci, Kolkata 741252, Mohanpur, India
[4] Symbiosis Int Univ, Hlth & Biomed Sci, Pune 412115, Maharashtra, India
[5] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[6] Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA
关键词
CANCER-THERAPY; BREAST-CANCER; CYTOTOXIC DRUG; LINKER; TRASTUZUMAB; COMPLEXES; ADC; PLATINUM(II); PAYLOADS; ALBUMIN;
D O I
10.1039/c6sc05149a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Despite the advances in the design of antibody-drug conjugates (ADCs), the search is still ongoing for novel approaches that lead to increased stability and homogeneity of the ADCs. We report, for the first time, an ADC platform technology using a platinum(II)-based linker that can re-bridge the inter-chain cysteines in the antibody, post-reduction. The strong platinum-sulfur interaction improves the stability of the ADC when compared with a standard maleimide-linked ADC thereby reducing the linker-drug exchange with albumin significantly. Moreover, due to the precise conserved locations of cysteines, both homogeneity and site-specificity are simultaneously achieved. Additionally, we demonstrate that our ADCs exhibit increased anticancer efficacy in vitro and in vivo. The Pt-based ADCs can emerge as a simple and exciting proposition to address the limitations of the current ADC linker technologies.
引用
收藏
页码:2387 / 2395
页数:9
相关论文
共 38 条
[1]   Contribution of linker stability to the activities of anticancer immunoconjugates [J].
Alley, Stephen C. ;
Benjamin, Dennis R. ;
Jeffrey, Scott C. ;
Okeley, Nicole M. ;
Meyer, Damon L. ;
Sanderson, Russell J. ;
Senter, Peter D. .
BIOCONJUGATE CHEMISTRY, 2008, 19 (03) :759-765
[2]  
Aullón G, 1999, CHEM-EUR J, V5, P1391
[3]   Synthesis of site-specific antibody-drug conjugates using unnatural amino acids [J].
Axup, Jun Y. ;
Bajjuri, Krishna M. ;
Ritland, Melissa ;
Hutchins, Benjamin M. ;
Kim, Chan Hyuk ;
Kazane, Stephanie A. ;
Halder, Rajkumar ;
Forsyth, Jane S. ;
Santidrian, Antonio F. ;
Stafin, Karin ;
Lu, Yingchun ;
Hon Tran ;
Seller, Aaron J. ;
Biroce, Sandra L. ;
Szydlik, Aga ;
Pinkstaff, Jason K. ;
Tian, Feng ;
Sinha, Subhash C. ;
Felding-Habermann, Brunhilde ;
Smider, Vaughn V. ;
Schultz, Peter G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (40) :16101-16106
[4]   Methods for site-specific drug conjugation to antibodies [J].
Behrens, Christopher R. ;
Liu, Bin .
MABS, 2014, 6 (01) :46-53
[5]   THE STRUCTURAL BASIS OF CAMPTOTHECIN INTERACTIONS WITH HUMAN SERUM-ALBUMIN - IMPACT ON DRUG STABILITY [J].
BURKE, TG ;
MI, ZH .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :40-46
[6]   New developments for antibody-drug conjugate-based therapeutic approaches [J].
de Goeij, Bart E. C. G. ;
Lambert, John M. .
CURRENT OPINION IN IMMUNOLOGY, 2016, 40 :14-23
[7]   Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies [J].
Ducry, Laurent ;
Stump, Bernhard .
BIOCONJUGATE CHEMISTRY, 2010, 21 (01) :5-13
[8]   Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985 [J].
Elgersma, Ronald C. ;
Coumans, Ruud G. E. ;
Huijbregts, Tiji ;
Menge, Wiro M. P. B. ;
Joosten, John A. F. ;
Spijker, Henri J. ;
de Groot, Franciscus M. H. ;
van der Lee, Miranda M. C. ;
Ubink, Ruud ;
van den Dobbelsteen, Diels J. ;
Egging, David F. ;
Dokter, Wim H. A. ;
Verheijden, Gijs F. M. ;
Lemmens, Jacques M. ;
Timmers, C. Marco ;
Beusker, Patrick H. .
MOLECULAR PHARMACEUTICS, 2015, 12 (06) :1813-1835
[9]   195Pt NMR spectroscopy:: A chemometric approach [J].
Gabano, Elisabetta ;
Marengo, Emilio ;
Bobba, Marco ;
Robotti, Elisa ;
Cassino, Claudio ;
Botta, Mauro ;
Osella, Domenico .
COORDINATION CHEMISTRY REVIEWS, 2006, 250 (15-16) :2158-2174
[10]   Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [J].
Goldenberg, David M. ;
Cardillo, Thomas M. ;
Govindan, Serengulam V. ;
Rossi, Edmund A. ;
Sharkey, Robert M. .
ONCOTARGET, 2015, 6 (26) :22496-22512